Data to be presented at the virtual European Academy of Neurology meeting next week in a late-breaking abstract related to ATA188, an allogeneic cell therapy being developed by Atara Biotherapeutics (ATRA), has been released.

The therapy also shows one Expanded Disability Status Scale, or EDSS, improvement in the five million cell cohort, and none in subjects given 10 million cells, according to Jacob Plieth of Evaluate Vantage. In the high-dose 40 million cells cohort, two of six subjects are showing EDSS improvement, according to Plieth, who cautions that "this is only at six months, and has yet to be confirmed with a 12-month reading."

In May 22 afternoon trading, shares of Atara were off their earlier highs, but remained up $2.47, or 16.5%, at $17.40 as of May 22.